A 42-year-old woman from Bangalore presents with involuntary choreiform movements of her limbs and face that are worse during stress and improve with sleep. She has a family history of similar illness in her mother and maternal grandfather. Cognitive assessment reveals mild memory impairment. Genetic testing confirms a CAG trinucleotide repeat expansion. Which basal ganglia circuit dysfunction best explains her hyperkinetic movement disorder?

Explanation

## Huntington's Disease: Basal Ganglia Circuit Pathophysiology ### Clinical Presentation Recognition **Key Point:** The vignette describes **Huntington's disease (HD)** — characterized by: - Choreiform (involuntary, dance-like) movements - Cognitive decline (dementia) - Psychiatric symptoms - Family history (autosomal dominant) - CAG trinucleotide repeat expansion (>36 repeats diagnostic) ### Normal vs. Huntington's Circuit | Feature | Normal Basal Ganglia | Huntington's Disease | |---------|---------------------|----------------------| | **Indirect pathway** | Medium spiny neurons (MSNs) with D2 receptors intact | Selective degeneration of D2+ MSNs (indirect pathway) | | **Direct pathway** | Medium spiny neurons with D1 receptors intact | D1+ MSNs (direct pathway) relatively preserved | | **Net effect** | Balanced inhibition and facilitation | **Unopposed direct pathway activity** | | **Thalamic output** | Normal inhibition from GPi/SNpr | Excessive disinhibition → hyperkinetic movement | | **Movement phenotype** | Normal | Hyperkinetic (chorea, dystonia) | ### Pathophysiology Mechanism 1. **Selective neuronal loss:** Huntingtin protein toxicity preferentially kills D2-expressing indirect pathway neurons in the striatum 2. **Indirect pathway collapse:** Loss of GPe → STN inhibition 3. **Direct pathway dominance:** D1+ neurons continue to inhibit GPi/SNpr, reducing thalamic inhibition 4. **Excessive thalamic disinhibition:** Reduced GPi output → excessive thalamic activation → hyperkinetic movements **High-Yield:** **Huntington's = loss of indirect pathway → unopposed direct pathway → hyperkinesia** (opposite of Parkinson's) ### Comparison: Hypokinetic vs. Hyperkinetic Disorders ```mermaid flowchart TD A["Basal Ganglia Disorder"]:::decision --> B{"Which pathway affected?"}:::decision B -->|"Indirect pathway lost"| C["Direct pathway unopposed"]:::outcome C --> D["Reduced GPi/SNpr inhibition of thalamus"]:::action D --> E["Hyperkinetic movement"]:::outcome E --> F["Huntington's, Chorea, Ballismus"]:::outcome B -->|"Dopamine lost"| G["Indirect pathway overactive"]:::outcome G --> H["Increased GPi/SNpr inhibition of thalamus"]:::action H --> I["Hypokinetic movement"]:::outcome I --> J["Parkinson's, Bradykinesia, Rigidity"]:::outcome classDef decision fill:#fbbf24,stroke:#b45309,color:#000 classDef action fill:#10b981,stroke:#047857,color:#fff classDef outcome fill:#2563eb,stroke:#1e40af,color:#fff ``` **Clinical Pearl:** Dopamine agonists worsen chorea in HD (by further facilitating the direct pathway), whereas they improve Parkinson's symptoms. This is a key clinical discriminator. ### Why Indirect Pathway Loss Causes Hyperkinesia - The indirect pathway is the **"brake"** on movement (it inhibits thalamus) - Loss of indirect pathway neurons = loss of the brake - Direct pathway (the **"accelerator"**) is unopposed - Result: **excessive, involuntary movement** **Mnemonic:** **"INDIRECT = INhibitor of movement; DIRECT = Drives movement"** - Lose INDIRECT (HD) → hyperkinesia (chorea) - Lose DOPAMINE (PD) → hypokinesia (bradykinesia) ### Neuropathology - Caudate and putamen atrophy (especially medial caudate) - Preferential loss of medium spiny neurons expressing D2 receptors - Relative sparing of D1+ neurons and interneurons - Huntingtin protein inclusions in neurons